FEATURED
Merck Announces $70 Billion U.S. Manufacturing and R&D Expansion
Merck & Co., Inc. announced on Monday a sweeping expansion of its U.S. operations, pledging more than $70 Billion in
DEALS
Pfizer Strikes Landmark Deal with Trump Administration to Cut Drug Prices for U.S. Patients
Pfizer Inc. has reached a sweeping agreement with the Trump Administration that will reduce prescription drug costs for U.S. patients
PRESS RELEASES
Journal Club: Gene-Agnostic Gene Therapy to Preserve Vision
Striatech is pleased to announce its next Journal Club: Gene-Agnostic Gene Therapy to Preserve Vision, which will be held on
EDITOR’S PICKS
Placing Regulatory Compliance at the Core of Pharmaceutical Supply Chains
Optimising Efficiency with Data Loggers In the fast-paced and highly regulated landscape of the pharmaceutical industry, ensuring compliance with stringent
RESOURCES
Enhancing RPE Metabolism to Protect Cone Vision in Retinitis Pigmentosa
Boosting RPE Metabolic Support Offers a Promising Gene-Independent Strategy for RP Treatment A Striatech .pdf Case Study Retinitis Pigmentosa (RP)
MANUFACTURING PROJECTS
Eli Lilly’s Next-gen $6.5B API and GLP-1 Orforglipron Facility, Houston, Texas, USA
Eli Lilly and Company has announced plans to build a $6.5 billion next-generation active pharmaceutical ingredient (API) manufacturing facility at
CLINICAL TRIALS
Lilly’s Jaypirca Outperforms Imbruvica in CLL Head-to-Head Phase 3 Trial
Eli Lilly’s Jaypirca (pirtobrutinib), the first and only FDA-approved non-covalent (reversible) BTK inhibitor, has met its primary endpoint in the
REGULATORY
Merck’s KEYTRUDA QLEX™ Secures FDA Approval as First Subcutaneous Pembrolizumab Injection
Merck & Co., known as MSD outside of the United States and Canada, announced on Saturday that the U.S. Food
SELECTED PRODUCTS
Customised Isolator Technology Solutions
BLOCK Technology provides customised isolator technology solutions. The company’s highly flexible, patented BLOCK®-type isolators can be adapted according to specific
